Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hematech was a pioneering biotechnology company specializing in the development of human polyclonal antibodies through transgenic animal technology. Based in Sioux Falls, South Dakota, the company developed a unique "transchromosomic" (Tc) bovine platform, where cattle were genetically engineered to carry human immunoglobulin genes. This allowed the animals to produce high titers of fully human polyclonal antibodies in response to specific antigens, offering a powerful tool for treating infectious diseases and biothreats. Hematech was acquired by Kirin Brewery Company (later Kyowa Kirin) in 2005 to bolster their antibody research capabilities. The technology and personnel from Hematech later formed the foundation for SAB Biotherapeutics, which continues to advance the Tc bovine platform today.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hematech.